# A Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Life

> **NCT02354105** · — · COMPLETED · sponsor: **UCB Biopharma S.P.R.L.** · enrollment: 680 (actual)

## Conditions studied

- Axial Spondyloarthritis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02354105
- **Lead sponsor:** UCB Biopharma S.P.R.L.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-12
- **Primary completion:** 2018-03-09
- **Final completion:** 2018-03-09
- **Target enrollment:** 680 (ACTUAL)
- **Last updated:** 2019-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02354105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02354105, "A Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Life". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02354105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*